

FORM 51-102F3 MATERIAL CHANGE REPORT

1. Name and Address of Company:

West Point Resources Inc. ("West Point" or the "Company")
7934 Government Road, Burnaby, BC, V5A 2E2

2. Date of Material Change:

June 5, 2014

3. News Release:

A news release disclosing the nature and substance of the material change was issued by the Corporation on June 16, 2014 through the news wire services of Marketwired.

4. Summary of Material Change:

On June 16, 2014, the Company announced that it has signed a definitive agreement with Cannabix Breathalyzer Inc. to license the North American rights to the Cannabix marijuana breathalyzer. The company has also received conditional approval from the Canadian Securities Exchange (CSE) for its listing application.

5. Full Description of Material Change:

On June 16, 2014, the Company announced that it has signed a definitive patent licensing agreement with Cannabix Breathalyzer Inc. to license the North American rights to the Cannabix marijuana breathalyzer.

Terms of the transaction

On June 5, 2014, the Company and Cannabix entered into a definitive licensing agreement. The definitive licensing agreement ("definitive agreement") provides West Point (the licensee) exclusive right, title, and interest in United States Patent Application Serial No. 61/981,650 No. 1 ("Licensed Patent") from Cannabix (the licensor). The territory covered in the agreement is the United States and its territories and possessions, and all other countries that are deemed to constitute the North American Continent. The consideration for the Licensed Patent is as follows: issuing 7.5 million common shares to current shareholders of Cannabix and issuing 7.5 million warrants exercisable at \$0.075, exercisable for one year to Cannabix Breathalyzer Inc. In addition, Cannabix have nominated two members to the Board of Directors of the Company.

Additional milestone payments

The definitive agreement outlines future share payments upon reaching the following milestones: The issuance of 7,500,000 of common shares of West Point within 14 business days of production of prototype of product. Furthermore, upon receipt of the final patent, the company will issue 5,000,000 common shares of West Point. There is no assurance that a prototype or that a final patent will be issued by the U.S. patent office.

Royalty on Licensed Patent

The Licensee shall pay Licensor a royalty of three percent (3%) of Licensee's selling price for each Licensed Product manufactured, used, or sold by Licensee in the Territory or imported by Licensee into the Territory.

Financing

The definitive agreement calls for the completion of a non-brokered financing for \$500,000 at \$0.05 cents per unit ("the concurrent financing"). Each Unit consists of one common share and one-half of one non-transferable common share purchase warrant exercisable at \$0.10 cents per common share for a period of 12 months from the date of closing. All warrants are subject to an early acceleration provision which provides for the mandatory exercise or expiry of the Warrants in the event West Point's shares close at \$0.13 or higher for at least 10 consecutive trading days. In such event, the Warrants will accelerate and expire 30 days after the Company has given notice of the accelerated conversion to the Warrant holders.

6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information:

Not applicable.

8. Executive Officer:

Inquiries in respect of the material change referred to herein may be made to:
Rav Mlait, President and Chief Executive Officer - (604) 551-7831

9. Date of Report:

June 23, 2014.